Ascidian Therapeutics' CEO discusses today's collaboration with Roche on the company's RNA exon editing technology for neurological conditions
Mike Ehlers describes how this $42M upfront and up to $1.8B in potential milestones deal is focused on neurological conditions, how RNA exon editing could be the right platform for this area of medicine, and why he thinks Roche is the right partner.